- Home
- VNRX vs BOLD Comparison
VNRX vs BOLD Comparison
Compare VNRX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNRX | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | VNRX | BOLD |
|---|---|---|
| Price | $0.25 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 2.1M | 142.4K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,007.00 | N/A |
| Revenue This Year | $55.98 | N/A |
| Revenue Next Year | $420.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $0.22 | $1.00 |
| 52 Week High | $0.94 | $3.12 |
Technical Indicators
Market Signals| Indicator | VNRX | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 51.99 |
| Support Level | $0.22 | $1.17 |
| Resistance Level | $0.26 | $1.37 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.44 | 34.00 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.